142 related articles for article (PubMed ID: 35704991)
1. [Direct medical costs in a cohort of patients with breast cancer].
de la Cruz-Aguirre K; Cortés-Sanabria L; Salas-González E; Canales-Muñoz JL; Aguayo-Alcaraz G; Ayala-Cortés RA; Palomares-Hernández CY
Rev Med Inst Mex Seguro Soc; 2022 Mar; 60(2):107-115. PubMed ID: 35704991
[TBL] [Abstract][Full Text] [Related]
2. [The health care costs of breast cancer: the case of the Mexican Social Security Institute].
Knaul FM; Arreola-Ornelas H; Velázquez E; Dorantes J; Méndez O; Avila-Burgos L
Salud Publica Mex; 2009; 51 Suppl 2():s286-95. PubMed ID: 19967284
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.
Khan SA; Hernandez-Villafuerte K; Hernandez D; Schlander M
Front Public Health; 2022; 10():946544. PubMed ID: 36684975
[TBL] [Abstract][Full Text] [Related]
4. [Cost of breast cancer treatment by clinical stage in the Basque Country, Spain].
Arrospide A; Soto-Gordoa M; Acaiturri T; López-Vivanco G; Abecia LC; Mar J
Rev Esp Salud Publica; 2015; 89(1):93-7. PubMed ID: 25946589
[TBL] [Abstract][Full Text] [Related]
5. Costs of breast cancer treatment prior to the introduction of immune-based therapy in Mexico.
Meneses-García A; Ramírez T; Ruiz-Godoy L; Chiquete E; Mohar A
Rev Med Inst Mex Seguro Soc; 2012; 50(1):19-24. PubMed ID: 22768813
[TBL] [Abstract][Full Text] [Related]
6. Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients.
John A; Baumgart A; Worst T; Heinzelbecker J
Urol Int; 2018; 100(3):279-287. PubMed ID: 29514158
[TBL] [Abstract][Full Text] [Related]
7. Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing.
Wilkinson AN; Seely JM; Rushton M; Williams P; Cordeiro E; Allard-Coutu A; Look Hong NJ; Moideen N; Robinson J; Renaud J; Mainprize JG; Yaffe MJ
Curr Oncol; 2023 Aug; 30(9):7860-7873. PubMed ID: 37754486
[TBL] [Abstract][Full Text] [Related]
8. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
9. Direct medical costs of breast cancer in Jordan: cost drivers and predictors.
Mousa R; Hammad E; Melhem J; Al-Jaghbir M
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):647-654. PubMed ID: 33353434
[No Abstract] [Full Text] [Related]
10. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
11. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
12. The cost of newly diagnosed breast cancer in Lithuania, 2011.
Ivanauskienė R; Domeikienė A; Kregždytė R; Milašauskienė Ž; Padaiga Ž
Medicina (Kaunas); 2015; 51(1):63-8. PubMed ID: 25744777
[TBL] [Abstract][Full Text] [Related]
13. Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review.
Palacios A; Rojas-Roque C; González L; Bardach A; Ciapponi A; Peckaitis C; Pichon-Riviere A; Augustovski F
Pharmacoeconomics; 2021 May; 39(5):485-502. PubMed ID: 33782865
[TBL] [Abstract][Full Text] [Related]
14. [Direct cost of complete cervical spinal cord injury].
Jiménez-Avila JM; Alvarez-Garnier JC; Bitar-Alatorre WE
Acta Ortop Mex; 2012; 26(1):10-4. PubMed ID: 23320334
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
16. Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios.
González-Robledo MC; Wong R; Ornelas HA; Knaul FM
Ecancermedicalscience; 2015; 9():587. PubMed ID: 26557885
[TBL] [Abstract][Full Text] [Related]
17. [Costs of medical care attributable to tobacco consumption at the Mexican Institute of Social Security (IMSS), Morelos].
Reynales-Shigematsu LM; Juárez-Márquez SA; Valdés-Salgado R
Salud Publica Mex; 2005; 47(6):451-7. PubMed ID: 16983991
[TBL] [Abstract][Full Text] [Related]
18. Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis.
Cortés-Sanabria L; Rodríguez-Arreola BE; Ortiz-Juárez VR; Soto-Molina H; Pazarín-Villaseñor L; Martínez-Ramírez HR; Cueto-Manzano AM
Perit Dial Int; 2013; 33(6):679-86. PubMed ID: 23547280
[TBL] [Abstract][Full Text] [Related]
19. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
20. The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data.
Park SK; Park JA; Yang SY; Shin JY; Koh H
Curr Med Res Opin; 2020 Nov; 36(11):1825-1833. PubMed ID: 32965131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
